Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of SYS6055 injection in relapsed or refractory aggressive B-cell lymphoma
CTR20260705Phase 2Active
- Sponsor
- Beijing Kangchuanglian Biopharmaceutical Technology Research Center
- Start
- Mar 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of SYS6055 in aggressive B-cell lymphoma, sponsored by Beijing Kangchuanglian Biopharmaceutical Technology Research Center. Started Mar 2026; status: active.
02
Drugs
SYS6055
03
Conditions
aggressive B-cell lymphoma
Beyond the preview
Go deeper on CTR20260705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260705.